A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors-Reference-Cited by-同舟云学术

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

Published:2014-06-11 Issue:5 Volume:32 Page:937-945
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Cleary James M.,Lima Caio Max S. Rocha,Hurwitz Herbert I.,Montero Alberto J.,Franklin Catherine,Yang Jianning,Graham Alison,Busman Todd,Mabry Mack,Holen Kyle,Shapiro Geoffrey I.,Uronis Hope

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-014-0110-9.pdf

Reference22 articles.

1. Azmi AS, Mohammad RM (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218(1):13–21

2. Del Gaizo Moore V (2008) and A. Letai, Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol 615:159–75

3. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15(4):1126–32

4. Leibowitz B, Yu J (2010) Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9(6):417–22

5. Tse C et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421–8

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MERTK Is a Potential Therapeutic Target in Ewing Sarcoma;Cancers;2024-08-12

2. Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions;Ageing Research Reviews;2024-06

3. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort;Investigational New Drugs;2024-01-25

4. Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature;European Journal of Medical Research;2024-01-09

5. Clinical advances in TNC delivery vectors and their conjugate agents;Pharmacology & Therapeutics;2024-01